• A Study for Reducing Alcohol Use During MOUD (Phase Two)

    Official Title Brief Digitally Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use during Medication for OUD (Phase Two)

    Purpose

    This study is being done to further examine and improve how a brief clinical treatment intervention may reduce alcohol use among patients engaged in medication for opioid use disorder (MOUD) treatment.

    The length of the study is approximately 10 weeks and will include two on-campus lab visits at Ohio State's Medical Campus, daily surveys via a smartphone app (surveys 3 times a day for ~21 days), three treatment sessions (completed online or in-person), and follow-up questionnaires (completed online). The total time commitment of the study is 11 hours and 6 minutes.

    Could this study be right for you?

    Inclusion Criteria:

    • engaged in MOUD treatment (for at least one month)
    • alcohol consumption (within the past 12 months)
    • age 18 or older
    • access to a smart phone

    (partial list of inclusion criteria)

    Exclusion Criteria:

    • diagnosis of psychosis or bipolar I
    • currently pregnant (positive pregnancy test)

    (partial list of exclusion criteria)

    Age Range

    18 years and up
  • A Study for Reducing Alcohol Use During MOUD (Phase One)

    Official Title Brief Digitally Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use during Medication for OUD (Phase One)

    Purpose

    This study is being done to adapt and improve a brief clinical treatment intervention that aims to reduce alcohol use among patients engaged in medication for opioid use disorder (MOUD) treatment.

    The length of the study is approximately 4 weeks and will include an initial study visit, daily surveys via a smartphone app (surveys 5 times a day for ~21 days), and three treatment sessions. All study sessions can be completed online or in-person. The total time commitment of the study is 8 hours and 30 minutes.

    Could this study be right for you?

    Inclusion Criteria:

    • engaged in MOUD treatment (for at least one month)
    • alcohol consumption (within the past 12 months)
    • age 18 or older
    • access to a smart phone

    (partial list of inclusion criteria)

    Age Range

    18 years and up
  • Evaluating the Safety and Usefulness of an Investigational Study Drug for Treating Patients with Bipolar Depression

    Official Title Depressive Episodes Associated with Bipolar I or II Disorder: A Double-Blind,
    Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of
    ABBV-932

    Purpose

    The purpose of this study is to see if the investigational study drug is safe and useful for treating patients with bipolar depression.

    Eligible participants will be randomized to receive the drug or placebo. A placebo looks just like the investigational study drug but has no active drug in it.

    The maximum duration of the study treatment period is 6 weeks. Participants receive psychiatric evaluation at each visit, and physical exam, urine test and blood draws at some of the visits. All study medication and procedures are provided at no cost, and participants may be compensated for their time and travel for each visit attended.

    Could this study be right for you?

    A diagnosis of bipolar disorder (type I or II) and be currently depressed.

    Age Range

    18 - 65 years
  • Postpartum Depression Study

    Official Title A Multicenter, Randomized, Double-Blind, Parallel-Group
    Dose-Controlled Study Evaluating the Safety and Efficacy of
    RE104 for Injection in the Treatment of Patients with
    Postpartum Depression (PPD)

    Purpose

    The purpose of this study is to compare the effectiveness of two doses of an experimental medication, administered once, in reducing symptoms of depression in patients with postpartum depression.

     

    Eligible participants will be assigned by chance to one of the two doses of the medication. The study includes 6 in-person visits and 4 telephone calls for up to 8 weeks.

    Could this study be right for you?

    To be eligible for this study, participants must meet the following criteria:

    • Female aged 18 to 45 years
    • Less than 12 months since delivery
    • Currently depressed
    • Not currently breastfeeding

    Age Range

    18 - 45 years
  • Psilocybin Study for Treatment - Resistant Depression

    Official Title A Phase III, multicentre, randomised, double-blind,
    controlled study to investigate the efficacy, safety,
    and tolerability of two initial administrations of
    COMP360 in participants with treatment-resistant
    depression

    Purpose

    The study investigates a new approach for treatment-resistant depression using an investigational medicine related to psilocybin alongside psychological support.

    Could this study be right for you?

    You may be able to join the study if you:

    —         Are 18 years of age or older

    —         Have been diagnosed with major depression and have not responded to 2+ antidepressants

    Other criteria will need to be met to confirm your eligibility for this study, which will last up to 62 weeks.

    Age Range

    18 years and up
  • A Depression Study Examining the Effects of Lumateperone in Treatment-Resistant Depression

    Official Title A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the
    Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of
    Patients with Major Depressive Disorder

    Purpose

    Depression is one of the most common mental health issues worldwide. Many people with major depressive disorder (MDD) take antidepressant medications that do not provide enough of a response to ease their depressive symptoms.

    The primary objective of this study is to evaluate the benefit of Lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) who have an inadequate response to ongoing ADT.

    Could this study be right for you?

    You may be able to take part if you:

    • are 18–65 years of age

    • have a confirmed diagnosis of Major Depressive Disorder (MDD)

    • feel that your current antidepressant medication is not working well

    • Has tried 2 or more antidepressant medication in the current episode of depression

     

    Other criteria will need to be met to confirm your eligibility for this study.

    Age Range

    18 - 65 years
  • Teen Depression Study

    Official Title Developing Rumination-Focused Treatment to Reduce Risk for Depression Recurrence (RDR) in Adolescence (RuMeChange)

    Purpose

    We are conducting a study looking at how therapy strategies can help teenagers stay healthy, reduce rumination, or overthinking and worrying, and prevent depression relapse. If eligible, the teenager would complete assessments which include clinical interviews over Zoom, surveys, cognitive testing, and an MRI.

    A parent/guardian is required to enroll in the study and will complete questionnaires and a clinical interview as well.

    Could this study be right for you?

    Inclusion Criteria:

    • 14-17 years of age at enrollment
    • Youth assent and parent consent

    Exclusion Criteria:

    • Metal braces, tattoos with metal
    • Claustrophobia
    • Current pregnancy

    Age Range

    14 - 17 years
  • Creating Culturally Responsive Early Childhood Programs: Hearing from Parents about what they want

    Official Title An Examination of Culturally Responsive, Inclusive, and Socially Just Practices Parent Feedback

    Purpose

    The research study will examine parents’ - or a child’s primary caregiver - perspectives on an online professional development (PD) training for teachers, targeting early care and education (ECE) teachers’ use of culturally responsive, inclusive, and socially just practices. Parents of young children will be recruited to review the online PD course and complete surveys about the course. A subset of participants will participate in a focus group to share their feedback on the course.

    Could this study be right for you?

    Parent or caregiver to a child who:

    • Is between 3 and 5 years old
    • Is identified as Black/African American
    • Attends a center-based early care and education program (pre-kindergarten, Head Start, child care, preschool, etc.)

    Age Range

    17 - 99 years
  • Social Abilities and Aging Study

    Official Title Progression of Social Cognitive Deficits in Mid- and Late-Life Schizophrenia Spectrum Disorders

    Purpose

    This research is being done to investigate the effects of age on social cognition in schizophrenia spectrum disorder. The study also hopes to examine potential neural bases of social cognition. The findings of the research will help develop effective treatment strategies by identifying who, when, and how to intervene.

    Could this study be right for you?

    Patients:

    • Diagnosis of a schizophrenia spectrum disorder (includes schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, schizophreniform disorder, unspecified or other-specified psychotic disorders)

    Healthy Controls:

    • No history of any psychotic disorder
    • No psychiatric diagnosis in the last 5 years
    • Not taking psychotropic medication

     

    Age Range

    35 - 75 years
  • MOMI Study

    Official Title The mom and infant outcomes (MOMI) study: A trial of perinatal outpatient delivery systems

    Purpose

    ​To improve our ability to provide the best possible care to every mom and infant, we are testing two different models of primary care during the first year after childbirth.

    Could this study be right for you?

    • You may qualify if you’re currently pregnant – AND – you’ve ever had high blood pressure, diabetes, depression, or anxiety, including during pregnancy.

    If you participate, you’ll be randomly assigned to an Ohio State location that delivers one of two models of care. Providers at all locations can help you manage your health, but the models differ in several ways.

    • You’ll complete three study visits with surveys, several measurements, and blood and hair sampling. We’ll collect cord blood and review medical records.